Author: admin

“Celiac Disease Market”

DelveInsight’s “Celiac Disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Celiac Disease, historical and forecasted epidemiology as well as the Celiac Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Celiac Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Celiac Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Celiac Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Celiac Disease market.

Recent breakthroughs in the Celiac Disease Market Report:

• Celiac disease is an autoimmune disorder triggered by the ingestion of gluten, which prompts an immune response that damages the lining of the small intestine. It affects approximately 1 in 100 people globally, but only about 30% are accurately diagnosed. The condition predominantly impacts females and is most commonly diagnosed in individuals aged 19-39, highlighting the importance of early detection and proper management.

• The primary treatment for celiac disease is a lifelong, strict gluten-free diet, which is crucial for alleviating symptoms, promoting intestinal healing, and preventing long-term complications. For patients experiencing celiac crisis or refractory celiac disease type II (RCD II), short-term use of corticosteroids such as prednisolone may provide relief until the gluten-free diet begins to take effect. Other treatment options for both RCD I and RCD II include budesonide, systemic corticosteroids, 6-mercaptopurine, cladribine, mesalamine, mycophenolate mofetil, and methotrexate.

• Despite following a gluten-free diet, about 5% of patients continue to experience symptoms, underscoring the urgent need for advanced treatment options and further research. In 2024, a pivotal study demonstrated that ZED1227, an investigational drug, successfully prevented gluten-induced intestinal damage by targeting specific molecular mechanisms, representing a significant advancement in celiac disease therapy.

• Recent progress was further highlighted in a July 2024 meeting, where the Beyond Celiac Coalition—a collaborative alliance of multidisciplinary experts—engaged with the FDA to promote a patient-centric approach to therapeutic trials. The aim was to enhance patient involvement while maintaining scientific rigor in developing new treatments.

• Leading pharmaceutical companies such as Entero Therapeutics, Amgen/Provention Bio, Takeda, and Sanofi are at the forefront of developing more effective therapies for celiac disease, offering new hope for improved management and better patient outcomes.

Celiac Disease Overview

Celiac disease is a chronic autoimmune disorder triggered by an abnormal immune response to gluten, a protein found in wheat, barley, and rye, in genetically predisposed individuals. The condition primarily affects the small intestine, causing inflammation and damage to the mucosal lining, leading to a range of gastrointestinal symptoms such as chronic diarrhea, abdominal pain, and malabsorption. It can also result in extraintestinal manifestations like anemia, osteoporosis, and neurological disturbances. The pathogenesis of celiac disease involves a complex interaction between genetic factors, notably the HLA-DQ2 and HLA-DQ8 haplotypes, and environmental triggers such as viral infections and changes in the gut microbiota. These factors disrupt gluten tolerance, activating T cells and inducing the production of autoantibodies, primarily targeting tissue transglutaminase (tTG), a key enzyme involved in gluten metabolism. Diagnosis can be challenging due to the wide range of clinical presentations and is typically confirmed through serological tests for specific antibodies and histological examination of intestinal biopsies.

This report provides an overview of the pathophysiology of celiac disease, diagnostic approaches, and a detailed treatment algorithm, alongside a real-world scenario illustrating a patient’s journey—from the onset of symptoms and the time to diagnosis, to the entire treatment process.

The cornerstone of celiac disease management is a strict, lifelong gluten-free diet, which allows the small intestine to heal and alleviates symptoms. Symptoms usually improve within weeks to months of dietary changes. A registered dietitian plays an essential role in helping patients with meal planning, label reading, and making healthy food choices. In some cases, additional treatments, such as vitamin and mineral supplements or corticosteroids to address persistent inflammation, may be required. Ongoing follow-up with a healthcare provider is essential for monitoring progress and ensuring nutritional adequacy. However, despite strict adherence to the gluten-free diet, some individuals may develop refractory celiac disease, necessitating further evaluation and alternative treatment options.

Learn more about Celiac Disease, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Celiac Disease Market Outlook 2034.

Celiac Disease Market 

The celiac disease market is poised for significant growth, driven by increased awareness, improved diagnostics, and a rising prevalence of the condition. As more cases are diagnosed, there is a growing demand for gluten-free products, specialized therapies, and advanced diagnostic tools. Major pharmaceutical companies, such as Entero Therapeutics, Amgen, Takeda, and Sanofi, are at the forefront of developing innovative treatments to meet the evolving needs of this expanding market.

• In 2023, the United States dominated the celiac disease market within the 7MM, representing around 70% of the total market share. 

• Among the EU4 and the UK, Italy led with an estimated market value of approximately USD 200 million for celiac disease. 

• In Japan, where the gluten-free diet remains the only effective treatment, the market for gluten-free products was valued at about USD 1,500 million in 2023.

Request a sample and discover more about the report offerings at: Celiac Disease Market Report 2034 Offerings

Celiac Disease Epidemiology 

The Celiac Disease epidemiology section provides insights into the historical and current Celiac Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Celiac Disease market report also provides the diagnosed patient pool, trends, and assumptions. 

• In 2023, the United States accounted for nearly 50% of the diagnosed prevalent cases of celiac disease across the 7MM. 

• Celiac disease exhibits a significant gender imbalance, with females being more commonly affected. For example, in Germany, approximately 60% of diagnosed cases are in women.

• In Japan, classical celiac disease represented about 30% of all celiac disease cases in 2023.

Explore more about Celiac Disease Epidemiology at: Celiac Disease Epidemiology Insights

Celiac Disease Drugs Uptake

This section focuses on the uptake rate of the potential Celiac Disease drugs recently launched in the Celiac Disease market or expected to be launched in 2020-2034. The analysis covers the Celiac Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Celiac Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Celiac Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The Celiac Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Celiac Disease key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Celiac Disease pipeline development activities at: Celiac Disease Therapy Assessment

Celiac Disease Emerging Therapy Assessment

• Larazotide Acetate (INN-202/AT-1001): 9 Meters Biopharma

• Latiglutenase (IMGX003/ALV003): ImmunogenX

• PRV-015: Provention Bio

• TAK-101: Takeda/Cour Pharmaceuticals

• AG017: Precigen ActoBio

• ZED1227: Falk Pharma and Zedira

• Celiac Disease Pipeline Development Activities

Celiac Disease Therapeutics Assessment

Major key companies are working proactively in the Celiac Disease Therapeutics market to develop novel therapies which will drive the Celiac Disease treatment markets in the upcoming years.

Learn more about the emerging therapies & key companies at: https://www.delveinsight.com/sample-request/celiac-disease-cd-market

Celiac Disease Report Key Insights

1. Celiac Disease Patient Population

2. Celiac Disease Market Size and Trends

3. Key Cross Competition in the Celiac Disease Market

4. Celiac Disease Market Dynamics (Key Drivers and Barriers)

5. Celiac Disease Market Opportunities

6. Celiac Disease Therapeutic Approaches

7. Celiac Disease Pipeline Analysis

8. Celiac Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Celiac Disease Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Celiac Disease Competitive Intelligence Analysis

4. Celiac Disease Market Overview at a Glance

5. Celiac Disease Disease Background and Overview

6. Celiac Disease Patient Journey

7. Celiac Disease Epidemiology and Patient Population

8. Celiac Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Celiac Disease Unmet Needs

10. Key Endpoints of Celiac Disease Treatment

11. Celiac Disease Marketed Products

12. Celiac Disease Emerging Therapies

13. Celiac Disease Seven Major Market Analysis

14. Attribute Analysis

15. Celiac Disease Market Outlook (7 major markets)

16. Celiac Disease Access and Reimbursement Overview

17. KOL Views on the Celiac Disease Market

18. Celiac Disease Market Drivers

19. Celiac Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Celiac Disease Market to Witness Growth by 2034, asserts DelveInsight | Takeda, ImmunogenX, Precigen ActoBio, Falk Pharma, Zedira, 9 Meters Biopharma

“Osteomyelitis Market Report 2032”

DelveInsight’s “Osteomyelitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Osteomyelitis, historical and forecasted epidemiology as well as the Osteomyelitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Some of the key facts of the Osteomyelitis Market Report: 

• The Osteomyelitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

• Key Osteomyelitis Companies: Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, Adaptive Phage Therapeutics, and others

• Key Osteomyelitis Therapies: DALVANCE (dalbavancin), Lefamulin, CF 296, Bacteriophage therapy, and others

• The diagnosed incidence cases of osteomyelitis in 7MM countries were ~162,000 in 2021.

• In May 2020, AbbVie announced that it had completed its acquisition of Allergan plc in a deal worth about USD 63 billion, following receipt of regulatory approval from all government authorities required by the transaction agreement and the Irish High Court.

• The Osteomyelitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Osteomyelitis pipeline products will significantly revolutionize the Osteomyelitis market dynamics.

Osteomyelitis Overview

Osteomyelitis represents a severe bone infection that can manifest as either an acute or chronic condition. This inflammatory ailment involves the bone and its structures and is typically triggered by pyogenic organisms that disseminate through the bloodstream, fractures, or surgical procedures. Normally, healthy and intact bone demonstrates resistance to infection. 

However, susceptibility to disease arises when a significant amount of bacteria is introduced, often due to trauma, restricted blood flow (ischemia), or the presence of foreign objects which expose binding sites for microorganisms. Infection can occur via several routes: hematogenous spread through the bloodstream from a distant source, contiguous dissemination from nearby tissues and joints, or direct introduction from trauma or surgery. Hematogenous osteomyelitis is more common in children, usually affecting long bones, while in adults, it often targets the vertebrae. Contiguous osteomyelitis is typically associated with trauma and related surgeries in younger adults, whereas in older adults, infections are commonly linked to pressure ulcers and infected joint replacements. 

Osteomyelitis related to vascular issues is prevalent among individuals with diabetes, particularly due to compromised blood flow in the lower limbs, leading to impaired local immunity and delayed wound healing, which facilitates the spread of infection. Hematogenous osteomyelitis tends to be caused by a single microbial agent, whereas infections stemming from contiguous spread or direct inoculation are usually caused by multiple or single microbes. The specific pathogens involved often vary depending on the patient’s age. 

Treating osteomyelitis effectively requires a multidisciplinary approach involving various medical and surgical specialties. Key components of therapy include surgically containing the infection and administering prolonged courses of antibiotics. Antibiotic treatment plays a central role and should be continued for an extended period. While laboratory tests can aid in diagnosis, they typically lack specificity for osteomyelitis. Variables such as leukocyte count, elevated erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels may or may not be present. Monitoring CRP levels can be particularly useful in assessing the response to treatment. Blood cultures may yield positive results, especially in cases of hematogenous osteomyelitis affecting specific bones. Radiographic imaging is crucial for evaluating suspected cases of osteomyelitis. Additionally, obtaining a bone biopsy, either through open surgery or percutaneous means, is essential for confirming the diagnosis, identifying the causative pathogen, and determining its susceptibility to guide antibiotic therapy.

Get a Free sample for the Osteomyelitis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/osteomyelitis-market

Osteomyelitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Osteomyelitis Epidemiology Segmentation:

The Osteomyelitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Osteomyelitis

• Prevalent Cases of Osteomyelitis by severity

• Gender-specific Prevalence of Osteomyelitis

• Diagnosed Cases of Episodic and Chronic Osteomyelitis

Download the report to understand which factors are driving Osteomyelitis epidemiology trends @ Osteomyelitis Epidemiology Forecast

Osteomyelitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Osteomyelitis market or expected to get launched during the study period. The analysis covers Osteomyelitis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Osteomyelitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Osteomyelitis Therapies

• DALVANCE (dalbavancin)

• Lefamulin

• CF 296

• Bacteriophage therapy

Osteomyelitis Key Companies

• Durata Therapeutics Inc

• Allergan plc

• Basilea Pharmaceutica

• Adaptive Phage Therapeutics

Discover more about therapies set to grab major Osteomyelitis market share @ Osteomyelitis Treatment Landscape

Osteomyelitis Treatment Market 

Optimal treatment of skeletal infections requires collaborative efforts of pediatricians, orthopedic surgeons, and interventional radiologists. Antibiotics can make up an effective treatment regimen but may include the surgical removal of dead bone in chronic osteomyelitis. Painkillers are given to ease the pain. In neglected cases with flexion contractures, prolonged physical therapy is required.

A few major unmet needs in the market include lack of novel and effective strategies for antibiotic therapy, challenges in diagnosis, difficulty in establishing microbial etiology, antimicrobial resistance, and lack of clarity in the role of surgical debridement in treating chronic osteomyelitis.

Osteomyelitis Market Opportunities

There are ongoing trials addressing unanswered questions, such as (CAR) T-cell therapy

Scope of the Osteomyelitis Market Report:

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Osteomyelitis Companies: Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, Adaptive Phage Therapeutics, and others

• Key Osteomyelitis Therapies: DALVANCE (dalbavancin), Lefamulin, CF 296, Bacteriophage therapy, and others

• Osteomyelitis Therapeutic Assessment: Osteomyelitis current marketed and Osteomyelitis emerging therapies

• Osteomyelitis Market Dynamics: Osteomyelitis market drivers and Osteomyelitis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Osteomyelitis Unmet Needs, KOL’s views, Analyst’s views, Osteomyelitis Market Access and Reimbursement 

To know more about Osteomyelitis companies working in the treatment market, visit @ Osteomyelitis Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Osteomyelitis Market Report Introduction

2. Executive Summary for Osteomyelitis

3. SWOT analysis of Osteomyelitis

4. Osteomyelitis Patient Share (%) Overview at a Glance

5. Osteomyelitis Market Overview at a Glance

6. Osteomyelitis Disease Background and Overview

7. Osteomyelitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Osteomyelitis 

9. Osteomyelitis Current Treatment and Medical Practices

10. Osteomyelitis Unmet Needs

11. Osteomyelitis Emerging Therapies

12. Osteomyelitis Market Outlook

13. Country-Wise Osteomyelitis Market Analysis (2019–2032)

14. Osteomyelitis Market Access and Reimbursement of Therapies

15. Osteomyelitis Market Drivers

16. Osteomyelitis Market Barriers

17.  Osteomyelitis Appendix

18. Osteomyelitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports: 

Osteomyelitis Pipeline  

“Osteomyelitis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Osteomyelitis market. A detailed picture of the Osteomyelitis pipeline landscape is provided, which includes the disease overview and Osteomyelitis treatment guidelines. 

Osteomyelitis Epidemiology 

DelveInsight’s ‘Osteomyelitis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Osteomyelitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Osteomyelitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Durata Therapeutics Inc, Allergan plc, Basilea Pharmaceutica, Adaptive Phage

“Pompe disease market”

DelveInsight’s “Pompe Disease Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Pompe Disease market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Pompe Disease market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Key highlights from the Pompe Disease Market Report:

• As per DelveInsight analysis, the Pompe disease market is expected to grow positively at a significant CAGR during the study period (2020–2034).

• Key pompe disease companies working in the pompe disease market are Genzyme, Sanofi, Amicus Therapeutics, Actus Therapeutics, Valerion Therapeutics, Astellas Therapeutics, Roche, Lacerta Therapeutics, and others.

• Some key therapies for Pompe disease treatment include ACTUS-101, AT845, Cipaglucosidase alfa, Avalglucosidase alfa (GZ402666), SPK-3006, and others.

• Pompe disease, also known as glycogen storage disease type II, is a rare inherited metabolic disorder caused by a deficiency of the enzyme acid alpha-glucosidase, which is essential for breaking down glycogen into glucose within lysosomes. When this enzyme is deficient, glycogen accumulates in various tissues, particularly muscle cells, leading to progressive damage. 

• In 2023, approximately 8,600 prevalent cases of Pompe disease were reported in the United States, with 98% of cases diagnosed in adult patients. A significant portion of Pompe disease cases are infantile-onset, which often results in high mortality within the first few months due to severe muscle weakness, poor muscle tone, and respiratory issues. This rapid progression causes considerable psychological distress for families.

• In the United States, the incidence of the CRIM-positive phenotype in infantile-onset Pompe disease was notably higher in 2023, reaching around 80%. The CRIM-positive phenotype is characterized by residual enzyme activity, which can influence both the disease’s progression and its response to treatment.

• Several enzyme replacement therapies for Pompe disease have been approved by the US FDA, including MYOZYME (alglucosidase alfa) and LUMIZYME (alglucosidase alfa) by Genzyme/Sanofi, and POMBILITI (cipaglucosidase alfa-atga) by Amicus Therapeutics.

• The Pompe disease treatment pipeline is still limited, with only a few candidates advancing through clinical trials. Notable candidates include AAV2/8-LSPhGAA (ACTUS-101) by Asklepios Biopharmaceutical in Phase I/II, and Avalglucosidase alfa by Sanofi, currently in Phase III. The rarity of Pompe disease presents challenges in patient recruitment for clinical trials, which in turn delays the development of new treatments.

Read detailed insights on Pompe Disease market outlook 2034 @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-Pompe Disease-market

Pompe Disease Overview

Pompe disease is a rare, inherited metabolic disorder caused by mutations in the GAA gene, leading to a deficiency in the enzyme acid alpha-glucosidase. This enzyme is crucial for breaking down glycogen into glucose within lysosomes. When the enzyme is deficient, glycogen accumulates in cells, particularly in muscles, resulting in progressive muscle weakness, respiratory issues, and other severe complications. Pompe disease has two primary forms: infantile-onset, which appears within the first few months of life and often leads to early mortality if untreated, and late-onset, which can develop from childhood to adulthood and progresses more slowly.

Diagnosis of Pompe disease typically involves enzyme assays to assess acid alpha-glucosidase activity in blood or muscle tissue, genetic testing to confirm GAA mutations, and muscle biopsies. Early detection is crucial for effective management, especially in the case of infantile-onset Pompe disease.

The main treatment for Pompe disease is enzyme replacement therapy (ERT), which replenishes the deficient enzyme. MYOZYME and LUMIZYME (both alglucosidase alfa), developed by Sanofi/Genzyme, have been the standard ERT treatments for many years. More recently, POMBILITI (cipaglucosidase alfa-atga), developed by Amicus Therapeutics, was approved as an alternative ERT. In addition, researchers are investigating gene therapy approaches, such as AAV2/8-LSPhGAA by Asklepios Biopharmaceutical, as potential future treatments.

Supportive care is also essential and typically includes respiratory management, physical therapy, and nutritional support to address the muscle weakness and respiratory difficulties common in Pompe disease. These interventions help preserve mobility, improve breathing, and manage complications.

Pompe Disease Epidemiology Insights

• According to DelveInsight’s estimates, the total number of prevalent Pompe disease cases in the 7MM (United States, EU4, and Japan) was approximately 13,000 in 2023, with projections showing an increase by 2034 at a compound annual growth rate (CAGR) of XX%.

• In 2023, EU4 and the UK accounted for approximately 25% of the total prevalent Pompe disease cases. In the United States alone, around 8,600 cases were diagnosed, with 98% of these cases reported in adult patients.

• A significant portion of Pompe disease cases are infantile-onset, which often leads to high mortality within the first few months due to severe muscle weakness, poor muscle tone, and respiratory difficulties. This rapid progression can cause considerable emotional distress for families.

• In 2023, the incidence of the CRIM-positive phenotype in infantile-onset Pompe disease was notably higher in the United States, reaching around 80%. The CRIM-positive phenotype, characterized by residual enzyme activity, can impact disease progression and influence the response to treatment.

Pompe Disease Epidemiology Segmentation:

• Total Pompe Disease Diagnosed Prevalent Cases

• Total Live Birth Cases of Pompe Disease

• Total Adult Cases of Pompe Disease

• Pompe Disease Type-specific Diagnosed Prevalent Cases

• Pompe Disease Treated Cases

Pompe Disease Treatment Market

In 2023, the total market for Pompe disease therapies across the seven major markets (7MM) was valued at USD 18.4 million, with the United States capturing approximately 70% of this market share. The US market significantly outpaced the EU4 (Germany, Spain, Italy, France), the UK, and Japan.

Within the EU4 and the UK, Germany held the largest market share, accounting for around USD 94 million, while France had the second-largest market, with [XX] representing the smallest market size in 2023.

Asklepios Biopharmaceutical is developing AAV2/8-LSPhGAA, a gene therapy candidate that aims to treat Pompe disease by delivering the GAA gene to restore enzyme function. Alongside Avalglucosidase alfa by Sanofi, which represents the next generation of enzyme replacement therapy (ERT), these candidates have the potential to address significant unmet needs in Pompe disease treatment. While early-stage results for AAV2/8-LSPhGAA are promising, pivotal trials will be crucial to confirm its safety and efficacy in humans.

Pompe Disease Therapies and Key Companies

• ACTUS-101: Asklepios Biopharmaceutical, Inc.

• AT845: Astellas Pharma Inc

• Cipaglucosidase alfa: Amicus Therapeutics

• Avalglucosidase alfa (GZ402666): Sanofi

• SPK-3006: Spark Therapeutics

Learn How the Pompe Disease Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/acute-respiratory-distress-syndrome-Pompe Disease-market

Pompe Disease Market Dynamics

The market for Pompe disease therapies has garnered increasing interest due to advancements in understanding the condition and developing innovative treatments. Several factors have driven these changes. Firstly, heightened awareness and enhanced diagnostic tools have led to earlier and more accurate diagnoses, increasing the patient population. This has prompted pharmaceutical companies to invest in research and development to create new therapies, including enzyme replacement and gene therapies. Additionally, regulatory agencies have played a pivotal role in shaping the market. Accelerated approval processes and orphan drug designations have motivated pharmaceutical companies to pursue treatments for Pompe disease. These factors, along with incentives for rare disease research, have created a more competitive landscape.

However, several challenges hinder the growth of the Pompe disease market. One significant obstacle is the high cost of developing and manufacturing therapies for rare diseases like Pompe. The limited patient population and specialized nature of these treatments result in high prices, which can complicate patient access and reimbursement. Another challenge is the disease’s complexity. Pompe disease shows considerable variability in its clinical presentation and progression, making it difficult to develop a universal treatment approach. Customizing therapies for individual patients is a goal, but it presents technical and regulatory challenges.

Furthermore, there is a need to raise awareness not only among the general public but also within the medical community. Many cases of Pompe disease are initially misdiagnosed due to its rarity, delaying appropriate treatment. In some regions, regulatory barriers can impede the introduction of innovative therapies, as local approval processes and reimbursement policies may not be well-suited to accommodating rare diseases.

Leading Players in the Pompe Disease Therapeutics Market Include:

Pompe Disease Companies working in the market are Genzyme, Sanofi, Amicus Therapeutics, Actus Therapeutics, Valerion Therapeutics, Astellas Therapeutics, Roche, Lacerta Therapeutics, and others.

Pompe Disease Report Covers the In-depth Assessment of the Emerging Pompe Disease Drugs & Key Companies. Download the Pompe Disease Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-Pompe Disease-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Pompe Disease Competitive Intelligence Analysis

4. Pompe Disease Market Overview at a Glance

5. Pompe Disease Disease Background and Overview

6. Pompe Disease Patient Journey

7. Pompe Disease Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Pompe Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Pompe Disease Unmet Needs

10. Key Endpoints of Pompe Disease Treatment

11. Pompe Disease Marketed Products

12. Pompe Disease Emerging Drugs and Latest Therapeutic Advances

13. Pompe Disease Seven Major Market Analysis

14. Attribute Analysis

15. Pompe Disease Market Outlook (In US, EU5, and Japan)

16. Pompe Disease Access and Reimbursement Overview

17. KOL Views on the Pompe Disease Market

18. Pompe Disease Market Drivers

19. Pompe Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market  | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pompe Disease Market is expected to rise at a Significant CAGR, DelveInsight | Pompe Disease Therapies, Clinical trials, Treatment Options, Companies | Genzyme, Sanofi, Amicus Therapeutics, Actus

“Hemophagocytic Lymphohistiocytosis Market”

DelveInsight’s ‘Hemophagocytic Lymphohistiocytosis Market Insights, Epidemiology, and Market Forecast – 2034’ report deliver an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Hemophagocytic Lymphohistiocytosis (HLH) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Hemophagocytic lymphohistiocytosis is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems. 

Key highlights from the Hemophagocytic lymphohistiocytosis Market Report:

• Hemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory syndrome caused by uncontrolled activation of the immune system. It is classified into two types: primary (familial) HLH, resulting from genetic mutations that impair immune regulation, and secondary (acquired) HLH, triggered by infections, cancers, or autoimmune disorders.

• In November 2024, Electra Therapeutics Receives FDA Fast Track Designation for ELA026 in Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

• In 2023, the 7MM reported approximately 4,500 new cases of HLH. Current treatment mainly includes therapies such as dexamethasone, etoposide, cyclosporine, intrathecal hydrocortisone, methylprednisolone, and rituximab. 

• The HLH market was valued at around USD 140 million in 2023, with expectations for significant growth due to increasing drug adoption, the potential launch of new therapies, and heightened awareness of the condition. The United States holds the largest share of the HLH market, surpassing the combined market size of the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

• Although the HLH pipeline is limited, a promising drug, ELA026, is in development. In June 2024, Electra Therapeutics presented clinical data for ELA026 in secondary HLH at the European Hematology Association (EHA) Congress in Madrid, with the results featured as one of six late-breaking oral presentations.

Hemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal hyperinflammatory syndrome caused by uncontrolled activation of the immune system. It is categorized into two types: primary (familial) HLH, which results from genetic mutations disrupting immune regulation, and secondary (acquired) HLH, which can be triggered by infections, malignancies, or autoimmune diseases. Common symptoms include fever, hepatosplenomegaly, pancytopenia, lymphadenopathy, and rash. The condition occurs due to the dysregulated activation of natural killer (NK) cells, cytotoxic T cells, and macrophages, leading to excessive inflammation and multi-organ damage.

Diagnosing HLH can be challenging because its symptoms are nonspecific, requiring a high level of suspicion. The Histiocyte Society’s diagnostic criteria are based on at least 5 out of 8 key findings: fever, splenomegaly, cytopenias in two or more lineages, hypertriglyceridemia or hypofibrinogenemia, hemophagocytosis in bone marrow/spleen/lymph nodes, hyperferritinemia, impaired NK cell function, and elevated soluble CD25 levels. Additional signs may include liver dysfunction (transaminitis), coagulopathy, hyponatremia, and neurological symptoms. Molecular testing can also aid in confirming the diagnosis. Early detection is critical, as HLH can be fatal without prompt intervention.

Click here and get access to free sample pages for the Hemophagocytic Lymphohistiocytosis Market Report 2034

As per the John Hopkins Medicine, there are 2 types of HLH: familial and acquired. Familial HLH accounts for about 25% of cases and families pass down the condition.  

The best treatment options for hemophagocytic lymphohistiocytosis (HLH) are determined by a number of factors, including the severity of symptoms, the age of onset, and the underlying cause of the condition.

Hemophagocytic lymphohistiocytosis Epidemiology Insights:

• In 2023, there were approximately 100 incident cases of familial hemophagocytic lymphohistiocytosis (HLH) in the United States. According to DelveInsight’s analysis, the distribution of genetic mutations associated with HLH included around 50 cases of PRF1 mutations, 35 cases involving STX11/STXBP2/UNC13D mutations, 10 cases of XIAP mutations, and 10 cases of NLRC4 or other mutations. 

• Additionally, in 2023, the United States saw approximately 130 cases of HLH related to malignancies, 135 cases linked to infections, 35 cases associated with autoimmune conditions, and 30 cases with unknown causes. 

• In the EU4 region and the UK, Germany recorded the highest number of incident HLH cases, while Spain reported the fewest.

Hemophagocytic lymphohistiocytosis Key pharma players involved:

1. A2B Bio Ltd

2. Bellicum Pharmaceuticals

Request for a detailed sample report: https://www.delveinsight.com/report-store/hemophagocytic-lymphohistiocytosis-market

Hemophagocytic Lymphohistiocytosis Market Insights:

• In 2023, the market size for hemophagocytic lymphohistiocytosis (HLH) in the United States was approximately USD 20 million. 

• Among the EU4 countries and the UK, France led the market with a size of around USD 30 million, followed by the UK at approximately USD 25 million. 

• The HLH market is expected to experience positive growth in the coming years, driven by the anticipated launch of emerging therapies such as ELA026.

Table of contents:

1 Key Insight

2 Executive Summary of Hemophagocytic Lymphohistiocytosis

3 Hemophagocytic Lymphohistiocytosis Market Overview at a Glance

4 Disease Background and Overview: Hemophagocytic Lymphohistiocytosis

5 Case Reports

6 Hemophagocytic Lymphohistiocytosis Epidemiology and Patient Population

7 United States Epidemiology

8 EU5 Epidemiology

9 Japan Epidemiology

10 Current Hemophagocytic Lymphohistiocytosis Treatment and Medical Practices

11 Unmet needs

12 Hemophagocytic Lymphohistiocytosis Marketed Drugs

13 Hemophagocytic Lymphohistiocytosis Emerging Drugs

14 Hemophagocytic Lymphohistiocytosis 7MM Market Analysis

15 United States

16 EU-5 countries: Market Outlook

17 Japan Market Outlook

18 Hemophagocytic Lymphohistiocytosis Market Drivers

19 Hemophagocytic Lymphohistiocytosis Market Barriers

20 SWOT Analysis

21 Reimbursement and market access

22 Appendix

23 DelveInsight Capabilities

24 Disclaimer

25 About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hemophagocytic Lymphohistiocytosis Market Size, Share, Epidemiology and Market Forecast 2034 | A2B Bio Ltd, Bellicum Pharmaceuticals, and others